Our Science – Feldman Website
Steven A. Feldman, Ph.D.
Selected Publications |
 |
| 1)
Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. J. Immunother. 36: 133-51, 2013. [Journal] |
|
| 2)
Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA. A Simple and Effective Method to Generate Lentiviral Vectors for ex Vivo Gene Delivery to Mature Human Peripheral Blood Lymphocytes. Hum Gene Ther Methods. 23: 73-83, 2012. [Journal] |
|
| 3)
Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA. Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application. J. Immunother. 35: 430-9, 2012. [Journal] |
|
| 4)
Morgan RA, Johnson LA, Davis J, Zheng Z, Woolard K, Feldman SA, Chinnasamy N, Kuan C, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 23: 1043-53, 2012. [Journal] |
|
| 5)
Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. Mol. Ther. 20: 246-9, 2012. [Journal] |
|
| 6)
Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME. Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement. J Immunother. 34: 651-61, 2011. [Journal] |
|
| 7)
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DN, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119: 2709-20, 2011. [Journal] |
|
| 8)
Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods. 366: 43-51, 2011. [Journal] |
|
| 9)
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CR, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J Clin Oncol. 29: 917-24, 2011. [Journal] |
|
| 10)
Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70: 3027-33, 2010. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 5/14/2013.
